Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-25T07:17:51.825Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Trial of Taractan in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

Eileen P. Scanlan  and
Arthur E. May
Eileen P. Scanlan
Affiliation:
Rainhill Hospital, Liverpool
Arthur E. May
Affiliation:
Rainhill Hospital, Liverpool
Get access Rights & Permissions [Opens in a new window]

Extract

The purpose of this trial was to evaluate the drug Taractan in the treatment of chronic schizophrenia.

Taractan (chlorprothixene) is chemically α-2-chloro-9-(w-dimethylamino propylidene)-thioxanthene. It is claimed to have neuroleptic and tranquillizing properties as well as thymoleptic activity. It is also claimed to be relatively free from side-effects. This property facilitated its use in a double-blind study.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 109 , Issue 460 , May 1963 , pp. 418 - 421
Copyright
Copyright © Royal College of Psychiatrists, 1963

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lorr, M., O'Connor, J. P., and Stafford, J. W., J. clin. Psychol., 1960, 16, (3), 241–245.3.0.CO;2-F>CrossRefGoogle Scholar
Siegel, S., Nonparametric Statistics for the Behavioural Sciences, 1956. McGraw Hill.Google Scholar
Guilford, J. P., Fundamental Statistics in Psychology and Education, 1956. McGraw Hill.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.